Crohn's Disease
Conditions
Keywords
Crohn's disease, IBD Cannabis, THC, CBD
Brief summary
There are many reports about efficacy of Cannabis in Crohn's disease but no controlled trials. The aim of the proposed trial is to investigate the efficacy of oil containing the cannabinoids THC and CBD given by mouth for induction of remission in Crohn's disease.
Detailed description
The investigators have recently published a retrospective observational study about the beneficial effect of cannabis in Crohn's disease. The investigators have also concluded a double blind placebo controlled study of Inhaled cannabis in the treatment of Crohn's disease. Both studies have shown significant symptomatic improvement of disease. However, objective parameters of inflammation were not measured. The question arises as to whether the observed improvement is merely symptomatic or due to a real change in inflammation. In addition, administration per os is a healthier option than smoking but the efficacy of oral cannabis was not investigated. The aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's disease patients compared to placebo. Treatment success will be defined as a decrease of at least 100 points in CDAI after 8 weeks of treatment. Secondary aims: 1. Remission of disease i.e CDAI of less the 150 points. 2. Improvement of at least one point in Endoscopic disease activity index 3. Improvement of CRP and calprotectine 4. Improvement of blood cytokine levels 5. Improvement of at least 30 points in quality of life as measured by the SF 36. In addition the investigators will monitor side effects by questionnaires addressed to the patients and to a significant relative of the patients.
Interventions
DRUGTHC 5mg/ml and CBS 50mg/ml
olive oil containing THC and CBD
DRUGPlacebo
olive oil without cannabis
Sponsors
Meir Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with a diagnosis of Crohn's disease of at least 3 months duration, which was proved by either endoscopy or appropriate imaging study. 2. Patients who have failed treatment with either 5 ASA or corticosteroids or immunomodulators or biologic agents, or steroid dependant patients, or patients who were treated by the above mentioned drugs and could not tolerate them due to side effects. 3. Age 20 or older. 4. Able to sign informed concent 5. Active Crohn's disease with a CDAI 200 or more. \-
Exclusion criteria
1. Patients with a diagnosis of a mental disorder 2. Patients who by the judgment of their physician are likely to develop drug addiction. 3. Pregnant women or women who are intending to become pregnant 4. Patients with a known cannabis allergy 5. Patients who are not capable of giving an informed consent 6. Patients with an impending operation due to Crohn's disease. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment sucsess will be defind as a decrease of at least 100 points in CDAI after 8 weeks of treatment. | 8 weeks | The aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's diseas patients compared to placebo. Treatment sucsess will be defind as a decrease of at least 100 points in CDAI after 8 weeks of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Remission of disease | 8 weeks | 1\. Remission of disease i.e CDAI of less the 150 points. |
| endoscopic improvment | 8 week | 2\. Improvment of at least one point in Endoscopic disease activity index |
| Improvment of blood cytokine levls | 8 weeks | blood cytokine levls including IL-10, TNF, and IL 23 will be measured before and at the end of the study |
| Improvment of at least 30 points in quality of life as measured by the SF 36. | 8 weeks | patients will answer a short form of Health related quality of life quasionnair before and at the end of the study. |
| Improvment of CRP and calprotectine | 8 week | CRP and calprotectine will be measured before and after 8 weeks of study treatment |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety and side effects | 8 weeks | we will monitor side effects by questionnairs adressed to the patients and to a significant relative of the patients.both patient and a significant realitive (parent, spouse) living in the same residence with the patient will recive a quationnair monitiring cannabis use, with aminimus score of 0 (not dependant, no side effects) to a maximum score of 15 (very dependant, sever side effects) |
Countries
Israel
Outcome results
None listed